Our findings reveal a potential mechanism underlying the functions of circME1 for promoting sunitinib resistance in ccRCC via cis-regulation of its parental gene ME1, which highlights a promising strategy to enhance clinical therapeutic efficacy of sunitinib with ME1 specific inhibitors in high-circME1 expression ccRCC patients. This evidence concerns the gene ME1 and nonpapillary renal cell carcinoma.